硒肽纳米药物激活 NK 细胞以增强肿瘤化学免疫治疗

Chemoimmunotherapy using nanotechnology has shown great potential for cancer therapy in the clinic.

However, uncontrolled transportation and synergistic responses remain challenges.

Here, a self-assembled selenopeptide nanoparticle that strengthens tumor chemoimmunotherapy through the activation of natural killer (NK) cells by the oxidative metabolite of the selenopeptide is developed. With the advantages of the enzyme-induced size-reduction and the reactive-oxygen-species-driven deselenization, this selenopeptide is able to deliver therapeutics, e. g. , doxorubicin (DOX), to solid tumors and further activate the NK cells in a programmed manner.

Importantly, in vitro and in vivo results prove the mutual promotion between the DOX-induced chemotherapy and the selenopeptide-induced immunotherapy, which synergistically contribute to the improved antitumor efficacy. It is anticipated that the selenopeptide may provide a type of promising stimuli-responsive immune modulator for versatile biomedical applications.